EyePoint (EYPT) Gross Margin (2018 - 2026)
EyePoint (EYPT) posted Gross Margin of 24.14% for Q1 2026, down 38.92% sequentially from 39.52% in Q4 2025, and down 7257.0% YoY from 0.34% in Q1 2025.
Powered by 
Analysis
EyePoint (EYPT) Gross Margin (2018 - 2026) Analysis & Trends
EyePoint has reported Gross Margin for 9 years, with the latest figure at 24.14% in Q1 2026.
- Quarterly Gross Margin fell 7257.0% year-over-year to 24.14% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 76.51% (down 1679.0% YoY) and the FY2025 annual result came in at 93.41%, up 199.0% from the prior year.
- Gross Margin declined to 24.14% in Q1 2026 per EYPT's latest filing, from 39.52% in the prior quarter.
- Over five years, Gross Margin peaked at 96.91% in Q2 2025 and troughed at 24.14% in Q1 2026.
- A 5-year average of 77.87% and a median of 85.97% in 2022 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2023 and 2026: Gross Margin soared 2526 bps in 2023, then tumbled 7257 bps in 2026.
- Over 5 years, Gross Margin stood at 67.63% in 2022, then jumped by 37 bps to 92.89% in 2023, then climbed by 0 bps to 92.96% in 2024, then sank by 57 bps to 39.52% in 2025, then tumbled by 39 bps to 24.14% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 24.14%, 39.52%, and 25.36% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 100.00% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 100.00% |
| Mar 31, 2026 | 24.14% |
| Dec 31, 2025 | 39.52% |
| Sep 30, 2025 | 25.36% |
| Jun 30, 2025 | 96.91% |
| Mar 31, 2025 | 96.71% |
| Dec 31, 2024 | 92.96% |
| Sep 30, 2024 | 93.01% |
| Jun 30, 2024 | 85.22% |
| Mar 31, 2024 | 93.50% |
| Dec 31, 2023 | 92.89% |
| Sep 30, 2023 | 92.09% |
| Jun 30, 2023 | 80.32% |
| Mar 31, 2023 | 91.67% |
| Dec 31, 2022 | 67.63% |
| Sep 30, 2022 | 85.97% |
| Jun 30, 2022 | 85.01% |
| Mar 31, 2022 | 80.88% |
| Dec 31, 2021 | 73.73% |
| Sep 30, 2021 | 79.85% |